Nano Dimension Ltd. (NNDM) is actively reshaping its corporate structure and strategic direction through a series of significant transactions. The company has announced a prospective merger with Infinite Epigenetics, aiming to capitalize on the burgeoning life sciences sector. Concurrently, NNDM has divested its MarkForged subsidiary, signaling a focused approach to its core industrial manufacturing technologies. These moves are designed to strengthen its financial position and unlock new avenues for expansion.
The proposed merger with Infinite Epigenetics represents a bold strategic pivot for Nano Dimension, indicating a desire to diversify beyond its traditional manufacturing solutions. This combination is expected to create a new entity focused on advanced epigenetics, offering shareholders exposure to a high-growth sector. Meanwhile, the sale of MarkForged demonstrates a commitment to optimizing its asset portfolio and streamlining operations to enhance overall value.
Transformative Merger with Infinite Epigenetics
Nano Dimension is pursuing a significant business combination with Infinite Epigenetics, outlining a non-binding term sheet for a complete acquisition. This proposed transaction envisions Nano Dimension, or a successor publicly traded entity, integrating Infinite Epigenetics through a merger or similar structure. If successful, the combined enterprise would operate under the Infinite Epigenetics brand and list on the Nasdaq Capital Market under a new ticker symbol, IEAI. Existing Nano Dimension shareholders are expected to retain a minority ownership stake, reflecting a 20% premium on Nano's estimated net cash at the time of closing. The parties anticipate the merged entity to possess over $400 million in cash. Furthermore, pre-combination Nano Dimension shareholders would receive contingent value rights tied to any net proceeds from the future sale of Nano's legacy assets. A 30-day exclusive period has been established for due diligence and finalization of the definitive merger agreement, with Matthew Dawson, co-founder and CEO of Infinite Epigenetics, slated to lead the new combined company.
This strategic alliance with Infinite Epigenetics is poised to redefine Nano Dimension's future trajectory. The acquisition of Infinite Epigenetics, a move into the high-growth epigenetics field, underscores Nano Dimension's ambition to broaden its market reach beyond industrial manufacturing. The proposed financial terms, including the premium offered to existing Nano Dimension shareholders and the significant cash reserves expected for the combined entity, highlight the potential for enhanced shareholder value. The careful structuring of contingent value rights for legacy assets also ensures that shareholders are protected and can benefit from future divestments. With a clear leadership plan in place under Matthew Dawson, the merger is intended to create a robust and forward-looking company at the intersection of advanced technology and life sciences, provided all due diligence and regulatory approvals are successfully completed within the exclusivity period.
Strategic Divestment of MarkForged
In a separate, yet equally significant strategic move, Nano Dimension recently finalized a definitive agreement for Stratasys to acquire MarkForged, a fully owned subsidiary of Nano Dimension. This all-cash transaction is valued at $42.5 million, subject to customary adjustments. MarkForged recorded approximately $70 million in revenue in 2025, which included its Metal Binder Jetting product line, a segment that Nano Dimension will retain post-acquisition. The completion of this transaction is projected for the latter half of 2026, contingent upon the fulfillment of standard closing conditions and obtaining the necessary regulatory approvals. This divestiture allows Nano Dimension to streamline its portfolio and sharpen its focus on its core industrial manufacturing solutions, particularly its additive manufacturing technologies for electronics and mechanical parts.
The sale of MarkForged to Stratasys is a crucial component of Nano Dimension's broader strategy to optimize its operations and enhance its financial liquidity. By divesting MarkForged, Nano Dimension not only secures a substantial cash inflow but also strategically retains key intellectual property and product lines, such as the Metal Binder Jetting technology, that align with its long-term vision. This move suggests a disciplined approach to capital allocation, allowing Nano Dimension to re-invest in its most promising areas of growth and innovation. The proceeds from this sale, combined with the expected cash from the Infinite Epigenetics merger, will provide the company with a strong financial foundation to pursue its strategic initiatives in industrial manufacturing and the newly entered epigenetics sector. This dual strategy of divestment and acquisition aims to position Nano Dimension for sustained growth and market leadership in its redefined operational scope.